These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37856079)

  • 1.
    Thyroid; 2023 Nov; 33(11):1385. PubMed ID: 37856079
    [No Abstract]   [Full Text] [Related]  

  • 2. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
    Brown SR; Hall A; Buckley HL; Flanagan L; Gonzalez de Castro D; Farnell K; Moss L; Gregory R; Newbold K; Du Y; Flux G; Wadsley J
    BMC Cancer; 2019 Jun; 19(1):582. PubMed ID: 31200667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.
    Wadsley J; Ainsworth G; Coulson AB; Garcez K; Moss L; Newbold K; Farnell K; Swain J; Howard H; Beasley M; Weaver A; Wood K; Marshall J; Griffin M; Pascoe A; Du Y; Taprogge J; Flux G; Brown S
    Thyroid; 2023 Sep; 33(9):1119-1123. PubMed ID: 37565288
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.
    Zhang L; Li Z; Zhang M; Zou H; Bai Y; Liu Y; Lv J; Lv L; Liu P; Deng Z; Liu C
    Med Oncol; 2023 Jul; 40(9):258. PubMed ID: 37524925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction to: Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study, by Kim M, Kim TH, Shin DY, Lim DJ, Kim EY, Kim WB, Chung JH, Shong YK, Kim BH, and Kim WG on behalf of Korean Thyroid Cancer Study Group (KTCSG). Thyroid 2018;28(3)340-348. DOI: 10.1089/thy.2017.0356.
    Thyroid; 2018 May; 28(5):686. PubMed ID: 29749906
    [No Abstract]   [Full Text] [Related]  

  • 6.
    Thyroid; 2024 Jan; 34(1):139. PubMed ID: 38165644
    [No Abstract]   [Full Text] [Related]  

  • 7. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
    Spitzweg C; Bible KC; Hofbauer LC; Morris JC
    Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.
    Shen H; Zhu R; Liu Y; Hong Y; Ge J; Xuan J; Niu W; Yu X; Qin JJ; Li Q
    Drug Resist Updat; 2024 Jan; 72():101013. PubMed ID: 38041877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.
    Tumino D; Frasca F; Newbold K
    Front Endocrinol (Lausanne); 2017; 8():312. PubMed ID: 29209273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
    Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
    BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer.
    Kebebew E; Lindsay S; Clark OH; Woeber KA; Hawkins R; Greenspan FS
    Thyroid; 2009 Sep; 19(9):953-6. PubMed ID: 19678746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.
    Lechner MG; Brent GA
    Clin Cancer Res; 2024 Apr; 30(7):1220-1222. PubMed ID: 38197869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selected Controversies of Radioiodine Imaging and Therapy in Differentiated Thyroid Cancer.
    Van Nostrand D
    Endocrinol Metab Clin North Am; 2017 Sep; 46(3):783-793. PubMed ID: 28760238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications.
    Van Nostrand D
    Thyroid; 2018 Sep; 28(9):1083-1093. PubMed ID: 30105931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
    Capdevila J; Krajewska J; Hernando J; Robinson B; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Williamson D; Levytskyy R; Oliver J; Keam B; Brose MS
    Thyroid; 2024 Mar; 34(3):347-359. PubMed ID: 38062732
    [No Abstract]   [Full Text] [Related]  

  • 16. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
    Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; Domínguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
    N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
    Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
    Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
    Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
    Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
    Cabanillas ME; Schlumberger M; Jarzab B; Martins RG; Pacini F; Robinson B; McCaffrey JC; Shah MH; Bodenner DL; Topliss D; Andresen C; O'Brien JP; Ren M; Funahashi Y; Allison R; Elisei R; Newbold K; Licitra LF; Sherman SI; Ball DW
    Cancer; 2015 Aug; 121(16):2749-56. PubMed ID: 25913680
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Thyroid; 2022 May; 32(5):603. PubMed ID: 35447040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.